Literature DB >> 26060019

Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy.

Pauline Maby1, David Tougeron2, Mohamad Hamieh1, Bernhard Mlecnik3, Hafid Kora1, Gabriela Bindea3, Helen K Angell4, Tessa Fredriksen3, Nicolas Elie5, Emilie Fauquembergue1, Aurélie Drouet1, Jérôme Leprince6, Jacques Benichou7, Jacques Mauillon8, Florence Le Pessot9, Richard Sesboüé1, Jean-Jacques Tuech10, Jean-Christophe Sabourin11, Pierre Michel12, Thierry Frébourg13, Jérôme Galon3, Jean-Baptiste Latouche14.   

Abstract

Colorectal cancers with microsatellite instability (MSI) represent 15% of all colorectal cancers, including Lynch syndrome as the most frequent hereditary form of this disease. Notably, MSI colorectal cancers have a higher density of tumor-infiltrating lymphocytes (TIL) than other colorectal cancers. This feature is thought to reflect the accumulation of frameshift mutations in sequences that are repeated within gene coding regions, thereby leading to the synthesis of neoantigens recognized by CD8(+) T cells. However, there has yet to be a clear link established between CD8(+) TIL density and frameshift mutations in colorectal cancer. In this study, we examined this link in 103 MSI colorectal cancers from two independent cohorts where frameshift mutations in 19 genes were analyzed and CD3(+), CD8(+), and FOXP3(+) TIL densities were quantitated. We found that CD8(+) TIL density correlated positively with the total number of frameshift mutations. TIL densities increased when frameshift mutations were present within the ASTE1, HNF1A, or TCF7L2 genes, increasing even further when at least one of these frameshift mutations was present in all tumor cells. Through in vitro assays using engineered antigen-presenting cells, we were able to stimulate peripheral cytotoxic T cells obtained from colorectal cancer patients with peptides derived from frameshift mutations found in their tumors. Taken together, our results highlight the importance of a CD8(+) T cell immune response against MSI colorectal cancer-specific neoantigens, establishing a preclinical rationale to target them as a personalized cellular immunotherapy strategy, an especially appealing goal for patients with Lynch syndrome. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26060019     DOI: 10.1158/0008-5472.CAN-14-3051

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  86 in total

1.  Marine omega-3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance).

Authors:  Mingyang Song; Fang-Shu Ou; Tyler J Zemla; Mark A Hull; Qian Shi; Paul J Limburg; Steven R Alberts; Frank A Sinicrope; Edward L Giovannucci; Erin L Van Blarigan; Jeffrey A Meyerhardt; Andrew T Chan
Journal:  Int J Cancer       Date:  2019-01-28       Impact factor: 7.396

2.  Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology-molecular associations: clinical and biological implications.

Authors:  Jinru Shia; Nikolaus Schultz; Deborah Kuk; Efsevia Vakiani; Sumit Middha; Neil H Segal; Jaclyn F Hechtman; Michael F Berger; Zsofia K Stadler; Martin R Weiser; Jedd D Wolchok; C Richard Boland; Mithat Gönen; David S Klimstra
Journal:  Mod Pathol       Date:  2016-12-16       Impact factor: 7.842

3.  Immune environment in serrated lesions of the colon: intraepithelial lymphocyte density, PD-1, and PD-L1 expression correlate with serrated neoplasia pathway progression.

Authors:  Gabriel Acosta-Gonzalez; Madhu Ouseph; Kara Lombardo; Shaolei Lu; Jonathan Glickman; Murray B Resnick
Journal:  Hum Pathol       Date:  2018-08-31       Impact factor: 3.466

4.  Cytotoxic T Cells and Granzyme B Associated with Improved Colorectal Cancer Survival in a Prospective Cohort of Older Women.

Authors:  Anna E Prizment; Robert A Vierkant; Thomas C Smyrk; Lori S Tillmans; Heather H Nelson; Charles F Lynch; Thomas Pengo; Stephen N Thibodeau; Timothy R Church; James R Cerhan; Kristin E Anderson; Paul J Limburg
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-12-15       Impact factor: 4.254

Review 5.  The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.

Authors:  Jeffrey P Ward; Matthew M Gubin; Robert D Schreiber
Journal:  Adv Immunol       Date:  2016-02-10       Impact factor: 3.543

6.  Intratumoural immune signature to identify patients with primary colorectal cancer who do not require follow-up after resection: an observational study.

Authors:  John N Primrose; Siân A Pugh; Gareth Thomas; Matthew Ellis; Karwan Moutasim; David Mant
Journal:  Health Technol Assess       Date:  2021-01       Impact factor: 4.014

7.  Multiparametric immune profiling in HPV- oral squamous cell cancer.

Authors:  Zipei Feng; Daniel Bethmann; Matthias Kappler; Carmen Ballesteros-Merino; Alexander Eckert; R Bryan Bell; Allen Cheng; Tuan Bui; Rom Leidner; Walter J Urba; Kent Johnson; Clifford Hoyt; Carlo B Bifulco; Juergen Bukur; Claudia Wickenhauser; Barbara Seliger; Bernard A Fox
Journal:  JCI Insight       Date:  2017-07-20

8.  Extracellular HSP110 skews macrophage polarization in colorectal cancer.

Authors:  Kevin Berthenet; Christophe Boudesco; Ada Collura; Magali Svrcek; Sarah Richaud; Arlette Hammann; Sebastien Causse; Nadhir Yousfi; Kristell Wanherdrick; Laurence Duplomb; Alex Duval; Carmen Garrido; Gaetan Jego
Journal:  Oncoimmunology       Date:  2016-04-22       Impact factor: 8.110

Review 9.  Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines.

Authors:  Jeanne Menez-Jamet; Catherine Gallou; Aude Rougeot; Kostas Kosmatopoulos
Journal:  Ann Transl Med       Date:  2016-07

10.  Frameshift mutations, neoantigens and tumor-specific CD8(+) T cells in microsatellite unstable colorectal cancers.

Authors:  Pauline Maby; Jérôme Galon; Jean-Baptiste Latouche
Journal:  Oncoimmunology       Date:  2015-11-24       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.